Discovery Services and Collaborations
Schrödinger engages in a wide range of drug discovery services and collaborations. To date Schrödinger has engaged in over 100 service agreements and collaborations, many of which have achieved success-based milestones, including successful progression to clinical trials.
Our Drug Discovery Group and Applications Scientists form a multi-disciplinary team within Schrödinger that comprises medicinal and computational chemists, many joined Schrödinger from the pharmaceutical industry after years of celebrated careers replete with patents and successful drug discovery programs.
Working alongside partners that range from leading academic groups and small biotechs to major pharmaceutical companies in the US and Europe, our team has tackled lead discovery, hit-to-lead, and lead optimization projects. A variety of drug targets have been addressed, including kinases, membrane proteins, enzymes, anti-viral, and anti-bacterial targets, as well as protein-protein interactions.
The wide range of projects we’ve successfully undertaken includes:
- Target validation
- Virtual screening
- Lead optimization (for potency, selectivity, and ADMET properties)
- Non-covalent, covalent, and allosteric inhibition
- Training on new technology
- Materials research
- Exploratory life science projects
- Movie creation
- Custom scripts
- KNIME and Python workflow generation
- Custom development of GUIs